Celcuity Rises Ahead of ASCO Update With FDA Deadline Pressing
Celcuity Inc. shares gained late Friday, topping the biotech sector as the company heads toward several cancer-drug updates, investor meetings, and an upcoming FDA decision date. Shares of the Minneapolis-based biotech traded at $132.88, adding $2.14, or around 1.6% on the day. The SPDR S&P Biotech ETF edged up roughly 0.5%. The iShares Nasdaq Biotechnology ETF was little changed.